Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Loss of Microtubule Protein Stathmin-1 Impairs Autophagy in Hematopoietic Stem Cells

Luana Chiquetto Paracatu, Qian Dong, Mia G Warmka, Liana Valin, Patrick Hunt, Ashley Jones, Meg Schuetz, Mousumi Chakraborty, Zev Greenberg, Christine RC Zhang, Grant A Challen, Cliff Luke, Robert Signer, Wandy Beatty, David Kast, Stephen Sykes, Laura G. Schuettpelz

Blood (2024) 144 (Supplement 1): 4041.

https://doi.org/10.1182/blood-2024-208205

Published: 2024

Journal Articles

Transmembrane Adaptor Protein Scimp Promotes TLR Signaling to Regulate Hematopoietic Stem Cell Function

Mousumi Chakraborty, Luana Chiquetto Paracatu, Zev Greenberg, Qian Dong, Ashley Jones, Laura G. Schuettpelz

Blood (2024) 144 (Supplement 1): 4040.

https://doi.org/10.1182/blood-2024-208139

Published: 2024

Journal Articles

Stathmin-1 Regulates Hematopoietic Stem Cell Mitochondrial and Cellular Function

Luana Chiquetto Paracatu, Qian Dong, Mia G Warmka, Liana Valin, Mousumi Chakraborty, Zev Greenberg, Nate Roundy, Christine RC Zhang, Grant A Challen, Cliff Luke, Wandy Beatty, Stephen M Sykes, Laura G. Schuettpelz

Blood (2023) 142 (Supplement 1): 4045.

https://doi.org/10.1182/blood-2023-189443

Published: 2023

Journal Articles

The Tetraspanin CD53 Promotes the Clonal Advantage of Dnmt3a-Deficient Hematopoietic Stem Cells

Mia G Warmka, Luana Chiquetto Paracatu, Mousumi Chakraborty, Qian Dong, Nate Roundy, Grant A Challen, Laura G. Schuettpelz

Blood (2023) 142 (Supplement 1): 5602.

https://doi.org/10.1182/blood-2023-180980

Published: 2023

Journal Articles

The tetraspanin CD53 protects stressed hematopoietic stem cells via promotion of DREAM complex–mediated quiescence

Zev J. Greenberg, Luana Chiquetto Paracatu, Darlene A. Monlish, Qian Dong, Michael Rettig, Nate Roundy, Rofaida Gaballa, Weikai Li, Wei Yang, Cliff J. Luke, Laura G. Schuettpelz

Blood (2023) 141 (10): 1180–1193.

https://doi.org/10.1182/blood.2022016929

Published: 2023

Includes: Supplemental data

Journal Articles

Genetic and Epigenetic Cis -Regulatory Disruptions Impacting the Canonical Wnt Signaling Repressor TLE1 Gene Promote Glucocorticoid Resistance in Childhood Acute Lymphoblastic Leukemia

Brennan P. Bergeron, Jonathan D. Diedrich, Yang Zhang, Kelly R. Barnett, Qian Dong, Daniel Ferguson, Robert J Autry, Wenjian Yang, Baranda S Hansen, Colton A Smith, Kristine R. Crews, Yiping Fan, Ching-Hon Pui, Shondra Miller, Mary V. Relling, Jun J. Yang, Chunliang Li, William E. Evans, Daniel Savic

Blood (2022) 140 (Supplement 1): 8838–8839.

https://doi.org/10.1182/blood-2022-166973

Published: 2022

Journal Articles

The Tetraspanin CD53 Promotes CXCR4 Signaling to Facilitate B Cell Migration

Mousumi Chakraborty, Zev J. Greenberg, Eric J. Duncavage, Nate Roundy, Qian Dong, Laura G. Schuettpelz

Blood (2022) 140 (Supplement 1): 8345–8346.

https://doi.org/10.1182/blood-2022-166906

Published: 2022

Journal Articles

Epigenetic Age Acceleration and Neurocognitive Function Among Long-Term Survivors of Pediatric Hodgkin Lymphoma: A Report from the St. Jude Lifetime Cohort

AnnaLynn M Williams, Qian Dong, Nicholas S. Phillips, Matt J. Ehrhardt, Deokumar Srivastava, Sedigheh Mirzaei Salehabadi, Yutaka Yasui, Kirsten K. Ness, Melissa M. Hudson, Leslie L. Robison, Kevin R. Krull, Zhaoming Wang

Blood (2022) 140 (Supplement 1): 2181–2182.

https://doi.org/10.1182/blood-2022-159026

Published: 2022

Journal Articles

The Role of Stathmin-1 in the Regulation of Hematopoietic Stem Cells

Luana Chiquetto Paracatu, Qian Dong, Zev J. Greenberg, Liana Valin, Nate Roundy, Christine R Zhang, Grant A Challen, Cliff Luke, Stephen M. Sykes, Laura G. Schuettpelz

Blood (2022) 140 (Supplement 1): 5734–5735.

https://doi.org/10.1182/blood-2022-166665

Published: 2022

Journal Articles

Mapping the Glucocorticoid Gene Regulatory Network and Alterations That Contribute to Steroid Resistance in Childhood Acute Lymphoblastic Leukemia

Brennan P. Bergeron, Jonathan Diedrich, Yang Zhang, Qian Dong, Daniel Ferguson, Robert J Autry, Wenjian Yang, Baranda S Hansen, Kristine R. Crews, Ching-Hon Pui, Yiping Fan, Shondra M. Pruett-Miller, Mary V. Relling, Jun J. Yang, Chunliang Li, William E. Evans, Daniel Savic

Blood (2021) 138 (Supplement 1): 674.

https://doi.org/10.1182/blood-2021-153002

Published: 2021

Journal Articles

The Tetraspanin CD53 Protects Hematopoietic Stem Cells Following Cellular Stress through Induction of DREAM Complex-Mediated Quiescence

Zev J. Greenberg, Darlene A. Monlish, Qian Dong, Luana Chiquetto Paracatu, Michael P. Rettig, Wei Yang, Weikai Li, Laura G. Schuettpelz

Blood (2021) 138 (Supplement 1): 295.

https://doi.org/10.1182/blood-2021-151010

Published: 2021

Journal Articles

Amino Acid Stress Response Genes Promote L-Asparaginase Resistance in Pediatric Acute Lymphoblastic Leukemia

Blood (2021) 138 (Supplement 1): 3304.

https://doi.org/10.1182/blood-2021-152940

Published: 2021

Journal Articles

CC-486 Reduces Hospitalization and Associated Estimated Costs in Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy: Results from the QUAZAR AML-001 Maintenance Trial

Esther Natalie Oliva, MD, Suman Kambhampati, MD, Albert Oriol, Ignazia La Torre, Barry Skikne, MD, C.L. Beach, PharmD, Keshava Kumar, PhD, Qian Dong, DrPH, Clara Chen, Sandip Ranjan, MTech, Zephirin Kiendrebeogo, Msc, PMP, Thorsten Braun, MD PhD

Blood (2020) 136 (Supplement 1): 14–15.

https://doi.org/10.1182/blood-2020-137562

Published: 2020

Journal Articles

CC-486 Prolongs Survival for Patients with Acute Myeloid Leukemia (AML) in Remission after Intensive Chemotherapy (IC) Independent of the Presence of Measurable Residual Disease (MRD) at Study Entry: Results from the QUAZAR AML-001 Maintenance Trial

Gail J. Roboz, MD, Farhad Ravandi, MBBS, Andrew H Wei, MBBS, PhD, Hervé Dombret, MD, Hartmut Döhner, Felicitas Thol, Maria Teresa Voso, MD, Andre C. Schuh, Kimmo Porkka, Ignazia La Torre, Barry Skikne, MD, Keshava Kumar, PhD, Qian Dong, DrPH, C.L. Beach, PharmD, Alberto Risueño, Daniel Lopes de Menezes, PhD, Gert Ossenkoppele, MD PhD

Blood (2020) 136 (Supplement 1): 32–33.

https://doi.org/10.1182/blood-2020-140837

Published: 2020

Journal Articles

Gastrointestinal Events and Management Strategies for Patients with Acute Myeloid Leukemia (AML) in First Remission Receiving CC-486 in the Randomized, Placebo-Controlled, Phase III QUAZAR AML-001 Maintenance Trial

Farhad Ravandi, MBBS, Christopher Pocock, MBBS, Dominik Selleslag, MD, Pau Montesinos, MD PhD, Hamid Sayar, MD MSc, Maurizio Musso, MD, Angela Figuera Alvarez, Hana Safah, MD, William Tse, MD FACP, Sang Kyun Sohn, MDPhD, Devendra K Hiwase, MBBS, MD FRACP, FRCPA, PhD, Timothy Chevassut, Francesca Pierdomenico, Ignazia La Torre, Barry Skikne, MD, Keshava Kumar, PhD, Qian Dong, DrPH, C.L. Beach, PharmD, Hervé Dombret, MD

Blood (2020) 136 (Supplement 1): 22–23.

https://doi.org/10.1182/blood-2020-137669

Published: 2020

Journal Articles

CC-486 Improves Overall Survival (OS) and Relapse-Free Survival (RFS) for Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy (IC), Regardless of Amount of Consolidation Received: Results from the Phase III QUAZAR AML-001 Maintenance Trial

Andrew Wei, MBBS,PhD, Gail J. Roboz, MD, Hervé Dombret, MD, Hartmut Döhner, Andre C. Schuh, Pau Montesinos, MD PhD, Christopher Pocock, MBBS, Dominik Selleslag, MD, Sergey N. Bondarenko, Ignazia La Torre, Barry Skikne, MD, Keshava Kumar, PhD, Qian Dong, DrPH, C.L. Beach, PharmD, Farhad Ravandi, MBBS

Blood (2020) 136 (Supplement 1): 38–40.

https://doi.org/10.1182/blood-2020-138498

Published: 2020

Journal Articles

The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission

Blood (2019) 134 (Supplement_2): LBA-3.

https://doi.org/10.1182/blood-2019-132405

Published: 2019

Journal Articles

CC-486 (Oral Azacitidine) in Patients with Hematological Malignancies Who Had Received Prior Treatment with Injectable Hypomethylating Agents (HMAs): Results from Phase 1/2 CC-486 Studies

Guillermo Garcia-Manero, MD, Michael R. Savona, MD, Steven D. Gore, MD, Bart L. Scott, MD, Christopher R. Cogle, MD, Thomas Boyd, MD, Paul Conkling, Joel Hetzer, PhD, Qian Dong, MS, Keshava Kumar, PhD, Stacey M. Ukrainskyj, BSN, Barry S. Skikne, MD

Blood (2016) 128 (22): 905.

https://doi.org/10.1182/blood.V128.22.905.905

Published: 2016

Journal Articles

CC-486 (Oral Azacitidine) Monotherapy in Patients with Acute Myeloid Leukemia (AML)

Michael R. Savona, MD, Steven D. Gore, MD, Kathryn S. Kolibaba, Stacey M. Ukrainskyj, BSN, Keshava Kumar, PhD, Qian Dong, MS, Joel Hetzer, PhD, Barry Skikne, MD, Guillermo Garcia-Manero, MD

Blood (2015) 126 (23): 452.

https://doi.org/10.1182/blood.V126.23.452.452

Published: 2015

Journal Articles

CC-486 in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML), or Chronic Myelomonocytic Leukemia (CMML): Safety, Tolerability, and Response

Michael R. Savona, MD, Kathryn Kolibaba, MD, Paul Conkling, MD, Edwin C. Kingsley, MD, Carlos Becerra, MD, John Morris, MD, Robert M. Rifkin, MD, Eric Laille, MS, Amy Kellerman, BA, Stacey M. Ukrainskyj, BSN,RN, Qian Dong, MS, Barry S. Skikne, MD

Blood (2014) 124 (21): 4638.

https://doi.org/10.1182/blood.V124.21.4638.4638

Published: 2014

NARROW

Loss of Microtubule Protein Stathmin-1 Impairs Autophagy in Hematopoietic Stem Cells

Transmembrane Adaptor Protein Scimp Promotes TLR Signaling to Regulate Hematopoietic Stem Cell Function

Stathmin-1 Regulates Hematopoietic Stem Cell Mitochondrial and Cellular Function

The Tetraspanin CD53 Promotes the Clonal Advantage of Dnmt3a-Deficient Hematopoietic Stem Cells

The tetraspanin CD53 protects stressed hematopoietic stem cells via promotion of DREAM complex–mediated quiescence

Genetic and Epigenetic Cis -Regulatory Disruptions Impacting the Canonical Wnt Signaling Repressor TLE1 Gene Promote Glucocorticoid Resistance in Childhood Acute Lymphoblastic Leukemia

The Tetraspanin CD53 Promotes CXCR4 Signaling to Facilitate B Cell Migration

Epigenetic Age Acceleration and Neurocognitive Function Among Long-Term Survivors of Pediatric Hodgkin Lymphoma: A Report from the St. Jude Lifetime Cohort

The Role of Stathmin-1 in the Regulation of Hematopoietic Stem Cells

Mapping the Glucocorticoid Gene Regulatory Network and Alterations That Contribute to Steroid Resistance in Childhood Acute Lymphoblastic Leukemia

The Tetraspanin CD53 Protects Hematopoietic Stem Cells Following Cellular Stress through Induction of DREAM Complex-Mediated Quiescence

Amino Acid Stress Response Genes Promote L-Asparaginase Resistance in Pediatric Acute Lymphoblastic Leukemia

CC-486 Reduces Hospitalization and Associated Estimated Costs in Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy: Results from the QUAZAR AML-001 Maintenance Trial

CC-486 Prolongs Survival for Patients with Acute Myeloid Leukemia (AML) in Remission after Intensive Chemotherapy (IC) Independent of the Presence of Measurable Residual Disease (MRD) at Study Entry: Results from the QUAZAR AML-001 Maintenance Trial

Gastrointestinal Events and Management Strategies for Patients with Acute Myeloid Leukemia (AML) in First Remission Receiving CC-486 in the Randomized, Placebo-Controlled, Phase III QUAZAR AML-001 Maintenance Trial

CC-486 Improves Overall Survival (OS) and Relapse-Free Survival (RFS) for Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy (IC), Regardless of Amount of Consolidation Received: Results from the Phase III QUAZAR AML-001 Maintenance Trial

The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission

CC-486 (Oral Azacitidine) in Patients with Hematological Malignancies Who Had Received Prior Treatment with Injectable Hypomethylating Agents (HMAs): Results from Phase 1/2 CC-486 Studies

CC-486 (Oral Azacitidine) Monotherapy in Patients with Acute Myeloid Leukemia (AML)

CC-486 in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML), or Chronic Myelomonocytic Leukemia (CMML): Safety, Tolerability, and Response

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only